R&G PharmaStudies Co. Ltd. A Net Asset Quality Index
R&G PharmaStudies Co. Ltd. A net asset quality index. R&G PharmaStudies Co. Ltd. A (301333) has a Net Asset Quality Index of 83.4% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥2.40 Billion minus total liabilities of CN¥397.56 Million yields net assets of CN¥2.00 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See R&G PharmaStudies Co. Ltd. A (301333) net assets for net asset value and shareholders' equity analysis.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of R&G PharmaStudies Co. Ltd. A (2019–2025)
Net asset quality index of R&G PharmaStudies Co. Ltd. A from 2019 to 2025. This chart shows how R&G PharmaStudies Co. Ltd. A's Net Asset Quality Index has evolved across 7 annual periods from 2019 to 2025. As of March 2026, the index stands at 83.4%, representing net assets of CN¥2.00 Billion against total assets of CN¥2.40 Billion CNY. Check 301333 tangible net assets ratio to evaluate the tangible quality of the company's equity base.
R&G PharmaStudies Co. Ltd. A Net Asset Quality Index by Year (2019–2025)
R&G PharmaStudies Co. Ltd. A net asset quality index by year from 2019 to 2025. The table below presents the year-by-year Net Asset Quality Index for R&G PharmaStudies Co. Ltd. A from 2019 to 2025, covering 7 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see R&G PharmaStudies Co. Ltd. A market cap and net worth.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 82.3% | CN¥1.98 Billion | CN¥2.40 Billion | CN¥423.89 Million | ▲ +3.7 pp |
| 2024 | 78.6% | CN¥1.84 Billion | CN¥2.34 Billion | CN¥500.09 Million | ▼ -6.0 pp |
| 2023 | 84.6% | CN¥1.75 Billion | CN¥2.07 Billion | CN¥319.17 Million | ▼ 0.0 pp |
| 2022 | 84.6% | CN¥1.59 Billion | CN¥1.88 Billion | CN¥289.35 Million | ▲ +20.0 pp |
| 2021 | 64.6% | CN¥437.81 Million | CN¥677.47 Million | CN¥239.66 Million | ▲ +1.8 pp |
| 2020 | 62.8% | CN¥336.98 Million | CN¥536.36 Million | CN¥199.38 Million | ▲ +6.9 pp |
| 2019 | 55.9% | CN¥249.74 Million | CN¥446.86 Million | CN¥197.12 Million | — |